JP2010520181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520181A5 JP2010520181A5 JP2009551228A JP2009551228A JP2010520181A5 JP 2010520181 A5 JP2010520181 A5 JP 2010520181A5 JP 2009551228 A JP2009551228 A JP 2009551228A JP 2009551228 A JP2009551228 A JP 2009551228A JP 2010520181 A5 JP2010520181 A5 JP 2010520181A5
- Authority
- JP
- Japan
- Prior art keywords
- osteopontin
- diabetes
- disease
- endothelial progenitor
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004264 Osteopontin Human genes 0.000 claims description 76
- 108010081689 Osteopontin Proteins 0.000 claims description 76
- 206010012601 diabetes mellitus Diseases 0.000 claims description 40
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 39
- 230000002792 vascular Effects 0.000 claims description 35
- 230000003511 endothelial effect Effects 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 24
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20070136 | 2007-03-02 | ||
| IE20070901 | 2007-12-10 | ||
| PCT/EP2008/052578 WO2008107422A1 (en) | 2007-03-02 | 2008-03-03 | Osteopontin for the prediction and treatment of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520181A JP2010520181A (ja) | 2010-06-10 |
| JP2010520181A5 true JP2010520181A5 (enExample) | 2012-04-19 |
Family
ID=39434086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551228A Pending JP2010520181A (ja) | 2007-03-02 | 2008-03-03 | 心血管疾患の予測および治療のためのオステオポンチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8323968B2 (enExample) |
| EP (1) | EP2114422A1 (enExample) |
| JP (1) | JP2010520181A (enExample) |
| AU (1) | AU2008223817A1 (enExample) |
| CA (1) | CA2679545A1 (enExample) |
| WO (1) | WO2008107422A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2596412A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| US20110008328A1 (en) * | 2007-04-17 | 2011-01-13 | Pfizer Inc. | Method for controlling glucose uptake and insulin sensitivity |
| WO2009085270A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
| EP2252689A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
| EP2240583A2 (en) * | 2008-01-07 | 2010-10-20 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| WO2011058182A1 (en) * | 2009-11-13 | 2011-05-19 | National University Of Ireland, Galway | Osteopontin-conditioned medium for the treatment of vascular diseases |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| CN111201247A (zh) | 2017-04-28 | 2020-05-26 | 奥克兰联合服务有限公司 | 治疗方法和新颖构建体 |
| WO2018202870A1 (en) * | 2017-05-04 | 2018-11-08 | Follicum Ab | Peptides for treatment of diabetes |
| JP7553115B2 (ja) * | 2018-11-07 | 2024-09-18 | フォリクム エービー | 糖尿病治療のためのペプチド断片 |
| WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
| WO2021183786A2 (en) * | 2020-03-11 | 2021-09-16 | University Of Florida Research Foundation, Incorporated | Methods, devices, and compositions for lesion repair and prevention |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| AU9510498A (en) * | 1997-09-26 | 1999-04-12 | University Of Washington | Methods and compositions for diagnosing renal pathologies |
| US6414219B1 (en) | 1998-06-30 | 2002-07-02 | Rutgers, The State University Of New Jersey | Osteopontin knock-out mouse and methods of use thereof |
| US6551990B2 (en) * | 1998-12-07 | 2003-04-22 | University Of Washington | Methods of inhibiting ectopic calcification |
| CA2810249A1 (en) * | 2000-06-05 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| AU2002357748A1 (en) * | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
| JP2006217801A (ja) * | 2003-01-15 | 2006-08-24 | Kirin Brewery Co Ltd | ＴＧＦβ阻害活性を有する化合物の新規用途 |
| JP2004222836A (ja) * | 2003-01-21 | 2004-08-12 | Tissue Engineering Initiative Co Ltd | 培養真皮シートの製造方法および培養真皮シート |
| AU2005219660B2 (en) * | 2004-03-09 | 2009-07-16 | Absorber Ab | Endothelial progenitor cells and methods of use thereof |
| CA2582353A1 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2006060779A2 (en) | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
| US20100150885A1 (en) * | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| FR2889200B1 (fr) * | 2005-07-27 | 2008-01-04 | Inst Vaisseaux Et Du Sang Ass | Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique |
| WO2007024649A2 (en) * | 2005-08-19 | 2007-03-01 | X-Cell Medical Incorporated | Methods of treating and preventing acute myocardial infarction |
-
2008
- 2008-03-03 AU AU2008223817A patent/AU2008223817A1/en not_active Abandoned
- 2008-03-03 US US12/528,610 patent/US8323968B2/en not_active Expired - Fee Related
- 2008-03-03 EP EP08717341A patent/EP2114422A1/en not_active Withdrawn
- 2008-03-03 JP JP2009551228A patent/JP2010520181A/ja active Pending
- 2008-03-03 CA CA002679545A patent/CA2679545A1/en not_active Abandoned
- 2008-03-03 WO PCT/EP2008/052578 patent/WO2008107422A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520181A5 (enExample) | ||
| Zhao et al. | Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction | |
| Davis et al. | Nongenomic actions of thyroid hormone | |
| Amin et al. | Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice | |
| Hanawa et al. | Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia | |
| Awada et al. | Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction | |
| Wolak | Osteopontin–a multi-modal marker and mediator in atherosclerotic vascular disease | |
| Taniguchi et al. | Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After ST-Elevated Acute Myocardial Infarction (EPOC-AMI)–A Pilot, Randomized, Placebo-Controlled Study– | |
| Cao et al. | Remote ischemic postconditioning (RIPC) of the upper arm results in protection from cardiac ischemia-reperfusion injury following primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) | |
| Sun et al. | TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease | |
| CN110462023B (zh) | 作为有效成分包括组蛋白去乙酰化酶抑制剂和激活因子的干细胞活性促进用组合物 | |
| Meng et al. | Osteopontin plays important roles in pulmonary arterial hypertension induced by systemic‐to‐pulmonary shunt | |
| Xiong et al. | Oxytocin ameliorates ischemia/reperfusion-induced injury by inhibiting mast cell degranulation and inflammation in the rat heart | |
| Watanabe et al. | Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases | |
| McCormick et al. | Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus | |
| Wang et al. | Myocardial protection by heparin-based coacervate of FGF10 | |
| Fu et al. | Gastrin exerts a protective effect against myocardial infarction via promoting angiogenesis | |
| Marks et al. | Thymosin β4: Roles in development, repair, and engineering of the cardiovascular system | |
| Lee et al. | Effect of lithium on ventricular remodelling in infarcted rats via the Akt/mTOR signalling pathways | |
| Cohen et al. | Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody | |
| Ren et al. | Subcutaneous administration of a nitric oxide-releasing nanomatrix gel ameliorates obesity and insulin resistance in high-fat diet-induced obese mice | |
| Pätilä et al. | Vascular endothelial growth factor C–induced collateral formation in a model of myocardial ischemia | |
| Lee et al. | Targeting the pathway of GSK-3β/nerve growth factor to attenuate post-infarction arrhythmias by preconditioned adipose-derived stem cells | |
| Boodhwani et al. | Insulin treatment enhances the myocardial angiogenic response in diabetes | |
| Schmidt et al. | Alginate sulfates mitigate binding kinetics of proangiogenic growth factors with receptors toward revascularization |